Menu

Reducing risk of further bleeding in cerebral amyloid angiopathy (CAA)

Who it’s for: Survivors of stroke
What it involves: Test a new treatment
Location: In-person VIC

Summary

This research study based at the Alfred Hospital and Royal Melbourne Hospital is evaluating the safety and feasibility of the medication tranexamic acid in reducing the risk of recurrent bleeding in patients with cerebral amyloid angiopathy (CAA).

Currently, there are no approved medications to prevent further bleeding in patients with CAA. This study will help researchers understand if this particular study medication can reduce the risk of bleeding without the increasing risk of serious side effects.

The study doctors will use blood tests to assess responses to the study medication in people with CAA and further understand this condition.

Eligibility

  • Probable diagnosis of CAA
  • Recent symptomatic intracranial bleeding within 6 months
  • Medical assessments as required
  • Able to have an MRI at baseline and 6-month follow-up.

Activity

  • There are two study sites in Melbourne, Victoria: The Alfred Hospital and Royal Melbourne Hospital.
  • Participation in this study will last for about 12 months.
  • Most activity happens in the first 6 months, which involves taking the study medication as instructed.
  • Blood tests are taken to measure the blood’s clotting ability, inflammation markers and biomarkers.
  • Attending appointments – some take place at the hospital research clinics, and some can be done remotely (by phone or video):

  1. Visit the research clinic for simple stroke assessments, questionnaires, and a review of medications and medical history (1 hour).
  2. Complete MRI brain imaging (1 hour ).
  3. At Week 12, join a 10–15 minute phone/video check-in.
  4. At Week 24, visit the research clinic for repeat checks and questionnaires (45 minutes) and a second MRI (1 hour).
  5. At Week 52, join a final 10–15 minute phone call.

Documents

Participant information sheet [DOCX 79 KB]

Contact

Pamela Galindo
Clinical Trial Manager – Stroke, Alfred Health

Phone: 03 9903 8655
Mobile: 0417 037 125
Email: tosccaatxa@alfred.org.au